Qutenza

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
N/0062	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	01/12/2023		PL	
II/0060	Update of sections 4.2 and 5.1 of the SmPC in order to update guidance to healthcare professionals regarding progressive response with repeated	14/09/2023	18/10/2023	SmPC	Update of the SmPC in order to update guidance to healthcare professionals regarding progressive response

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	treatments. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				with repeated treatments.
IB/0061	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	09/08/2023	n/a		
IB/0059	B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms	29/05/2023	18/10/2023	SmPC	
II/0057	Update of sections 4.4 and 4.8 of the SmPC in order to add `Third Degree Burn´ to the list of adverse drug reactions (ADRs) with frequency not known, based on a validated safety signal and post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	26/04/2023	18/10/2023	SmPC and PL	Not applicable
IB/0058	B.II.e.1.z - Change in immediate packaging of the finished product - Other variation	08/03/2023	n/a		

IA/0056	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	07/06/2022	n/a		
PSUSA/533/202105	Periodic Safety Update EU Single assessment - capsaicin	13/01/2022	n/a		PRAC Recommendation - maintenance
N/0053	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	21/09/2021	18/10/2023	PL	
IB/0052	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	24/02/2021	n/a		
II/0051/G	This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	28/01/2021	09/07/2021	SmPC and PL	Based on recent post marketing studies reflecting current Qutenza clinical use and changes in recommendations for opioid prescription for acute pain, SmPC is updated to delete the explicit reference to local pre-treatments used in clinical trials and to opioids. SmPC is also updated to include more detail on unintended exposure to capsaicin. For more information, please refer to the Summary of Product Characteristics.
IA/0050/G	This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	15/09/2020	n/a		

	Replacement/addition of a site where batch control/testing takes place				
II/0048	Update of sections 4.2 and 5.1 of the SmPC in order to amend the posology based on PACE and STRIDE studies. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	30/04/2020	31/07/2020	SmPC and PL	The SmPC section 4.2 and 5.1 have been updated in order to amend the posology based on PACE and STRIDE studies. The Package Leaflet is updated accordingly.
II/0049	Update of section 4.8 of the SmPC in order to update the safety information on adverse reactions frequencies based on latest clinical data pooling; the Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	16/07/2020	09/07/2021	SmPC and PL	Update of section 4.8 of the SmPC to include revised adverse reactions frequencies based on latest clinical data pooling.
R/0047	Renewal of the marketing authorisation.	31/01/2019	28/03/2019	SmPC, Labelling and PL	
IA/0046	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	04/06/2018	n/a		

N/0045	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/08/2017	09/07/2018	PL	
IAIN/0044/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	20/07/2017	09/07/2018	Annex II, Labelling and PL	
T/0043	Transfer of Marketing Authorisation	13/03/2017	04/05/2017	SmPC, Labelling and PL	
PSUSA/533/201605	Periodic Safety Update EU Single assessment - capsaicin	12/01/2017	n/a		PRAC Recommendation - maintenance
IB/0041/G	This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	18/05/2016	n/a		

	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -				

	Replacement/addition of a site where batch control/testing takes place B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter				
IA/0040	B.II.e.3.c - Change in test procedure for the immediate packaging of the finished product - Deletion of a test procedure if an alternative test procedure is already authorised	21/12/2015	n/a		
II/0039	Extension of Indication to include treatment of diabetic patients with peripheral neuropathic pain based on the results of studies E05-CL-3004 (STEP) and E05-CL-3002 (PACE) for Qutenza. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC have been updated. The Package Leaflet Annex II and Labelling are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives for Belgium in the Package Leaflet. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC, Annex II, labelling and Package Leaflet. An updated RMP (version 18.3) has been approved as part of the application. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	23/07/2015	20/08/2015	SmPC, Annex II, Labelling and PL	Please refer to the scientific discussion Qutenza-H-C-909-H-C-II-39.
PSUSA/533/2	Periodic Safety Update EU Single assessment -	04/12/2014	n/a		PRAC Recommendation - maintenance

01405	capsaicin				
II/0037	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	23/10/2014	n/a		
IA/0036	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	27/06/2014	n/a		
R/0031	Renewal of the marketing authorisation.	20/02/2014	23/04/2014	SmPC, Annex II, Labelling and PL	Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of Qutenza remains positive, however the Committee requested an additional five year renewal on the basis of the following pharmacovigilance grounds: several safety concerns which could impact on the benefit-risk balance of the product require further evaluation or close monitoring including bradycardia, chest pain, application site reactions, second degree burns, off label use, accidental exposure; further important safety data are expected from on-going post-authorisation studies.
IB/0035	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	03/04/2014	n/a		
PSUSA/533/201305	Periodic Safety Update EU Single assessment - capsaicin	05/12/2013	n/a		PRAC Recommendation - maintenance
IA/0034	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP -	12/11/2013	n/a		

	Replacement/addition of a site where batch control/testing takes place				
IA/0032	B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits	16/10/2013	n/a		
IAIN/0030	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	01/08/2013	n/a		
IAIN/0029/G	This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	07/05/2013	n/a		
IAIN/0028	C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV	18/03/2013	n/a		
IAIN/0027	A.1 - Administrative change - Change in the name and/or address of the MAH	27/02/2013	12/03/2014	SmPC, Labelling and PL	

IAIN/0026/G	This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	08/02/2013	n/a		
II/0024	Update of section 4.2 of the SmPC in order add the possibility to use Qutenza without pre-treatment with a topical anaesthetic or to substitute it for an oral analgesic and to further substantiate current instructions for patch application. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is being brought in line with the latest QRD template version 8.1. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	15/11/2012	11/03/2013	SmPC, Annex II, Labelling and PL	Results from study QTZ-EC-0002, a randomized, multi-center, assessor-blinded study of the tolerability of Qutenza when applied after pre-treatment with lidocaine or tramadol in subjects with peripheral neuropathic pain, in combination with post-marketing experience, indicated that in some patients, lidocaine pre-treatment can be either avoided or substituted with oral tramadol with no impact on the patch tolerance and therefore the treatment efficacy. Section 4.2 of the SmPC was updated to allow the treating physician to adapt the care of the patient accordingly. In addition the instructions for patch application were further substantiated to enhance appropriate execution of the complete procedure.
IB/0025	C.I.9.z - Changes to an existing pharmacovigilance system as described in the DDPS - Other variation	07/09/2012	n/a		
IAIN/0023/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance	03/02/2012	n/a		

	system as described in the DDPS - Change in the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
IA/0022	B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place	17/01/2012	n/a		
IA/0021/G	This was an application for a group of variations. B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.III.2.b - Change to comply with Ph. Eur. or with a	21/11/2011	n/a		

	national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)				
IA/0019/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the	07/04/2011	n/a		

	contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				
II/0014	Update of the SPC section 4.2 to change the description of pre-treatment procedures. In addition the MAH took the opportunity to make a few editorial amendments to the SPC, Annex II, Labelling and Package Leaflet. The addresses of the local representatives have been deleted from the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	20/01/2011	21/02/2011	SmPC, Annex II, Labelling and PL	IIn previous studies, mostly topical 4 % Lidocaine was used to provide local analgesia prior to application of Qutenza to enhance the tolerability of the Qutenza treatment procedure. In a new study in post herpetic neuralgia patients (Study C123) the tolerability of an alternative to 4% lidocaine, namely lidocaine (2.5%)/prilocaine (2.5%) cream, was evaluated. The description of pre-treatment procedures in Section 4.2 of the SPC for Qutenza was changed from "a 4% topical Lidocaine" to "topical Lidocaine 4% or Lidocaine (2.5%)/prilocaine (2.5%)".
IB/0018	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation	08/12/2010	n/a		
IA/0017/G	This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its	03/12/2010	n/a		

	corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0016	B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter	12/11/2010	n/a		
IA/0015	A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)	28/10/2010	n/a		
IA/0013/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph	17/09/2010	n/a		

	of the Ph. Eur. or national pharmacopoeia of a Member State				
IA/0012/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	13/08/2010	n/a	Annex II	
IA/0010/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph	26/05/2010	n/a		

	of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IA/0009	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	23/04/2010	n/a		
IA/0008	B.IV.1.b - Change of a measuring or administration device - Deletion of a device	11/02/2010	n/a	SmPC, Labelling and PL	
II/0002	Update of DDPS (Pharmacovigilance) Update of DDPS (Pharmacovigilance)	17/12/2009	25/01/2010	Annex II	The Detailed Description of the Pharmacovigilance System (DDPS) has been updated in order to reflect the change in Marketing Authorisation Holder. Consequently, Annex II has been to reflect the new version number (5.0) of the agreed DDPS.
IB/0004	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure IB_37_b_Change in the specification of the finished product - add. of new test parameter	08/01/2010	n/a		
IA/0006	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	22/12/2009	n/a		
IA/0005	IA_38_a_Change in test procedure of finished product - minor change to approved test procedure	04/12/2009	n/a		

IA/0003	IA_20_a_Change in test procedure for an excipient - minor change to approved test procedure	24/11/2009	n/a		
T/0001	Transfer of Marketing Authorisation	08/09/2009	25/09/2009	SmPC, Labelling and PL	